Pharsight

Tazorac patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5914334 ALLERGAN Stable gel formulation for topical treatment of skin conditions
Jun, 2014

(9 years ago)

US6258830 ALLERGAN Stable gel formulation for topical treatment of skin conditions
Jun, 2014

(9 years ago)

Tazorac is owned by Allergan.

Tazorac contains Tazarotene.

Tazorac has a total of 2 drug patents out of which 2 drug patents have expired.

Expired drug patents of Tazorac are:

  • US5914334
  • US6258830

Tazorac was authorised for market use on 13 June, 1997.

Tazorac is available in gel;topical dosage forms.

Tazorac can be used as stable gel formulation for topical treatment of skin conditions.

The generics of Tazorac are possible to be released after 07 June, 2014.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using TAZAROTENE ingredient

Market Authorisation Date: 13 June, 1997

Treatment: Stable gel formulation for topical treatment of skin conditions

Dosage: GEL;TOPICAL

More Information on Dosage

TAZORAC family patents

Family Patents